Actively Recruiting
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
Led by Nanjing University · Updated on 2025-08-19
590
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.
CONDITIONS
Official Title
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 20 to 37 years inclusive
- Diagnosed with infertility and undergoing IVF/ICSI treatment using a long-acting GnRH agonist protocol
- Serum luteinizing hormone (LH) level less than 0.5 U/L after pituitary downregulation
- Normal uterine cavity confirmed by hysteroscopy, sonohysterography, or hysterosalpingography within the last 6 months
- Provided written informed consent before participation
You will not qualify if you...
- Polycystic ovary syndrome (PCOS)
- History of recurrent implantation failure (RIF)
- Presence of endometriosis or adenomyosis
- History of ovarian surgery
- Ovarian cysts 3 cm or larger or suspected malignancy
- Poor ovarian reserve (antral follicle count less than 5, anti-M�fcllerian hormone less than 1.1 ng/mL, or baseline FSH greater than 10 IU/L)
- Chromosomal abnormalities in either partner
- Systemic diseases such as uncontrolled hypertension, diabetes, thyroid disorders, or autoimmune diseases
- Contraindications to ovarian stimulation medications or pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing Drum Tower Hospital, Nanjing University Medical School
Nanjing, Jiangsu, China, 210008
Actively Recruiting
Research Team
Y
Yue Jiang, PhD
CONTACT
H
Hui Zhang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here